GlycoMimetics Inc.

11/15/2021 | Press release | Distributed by Public on 11/15/2021 06:10

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)